The Time Has Come for Targeted Therapies for AML: Lights and Shadows

Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs...

Full description

Saved in:
Bibliographic Details
Published in:Oncology and therapy 2020-06, Vol.8 (1), p.13-32
Main Authors: Fiorentini, Alessandro, Capelli, Debora, Saraceni, Francesco, Menotti, Diego, Poloni, Antonella, Olivieri, Attilio
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Enasidenib
Gemtuzumab ozogamicin
Genetoclax
Gilteritinib
Glasdegib
Internal Medicine
Leukemia
Medicine
Medicine & Public Health
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs by the Food and Drug Administration (FDA) within the last 2 years, providing new opportunities, as well as new challenges, for treating clinicians. These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibitor glasdegib, and BCL-2 inhibitor venetoclax. In this review, we summarize currently available data on these new drugs and discuss the rapidly evolving therapeutic armamentarium for AML, focusing on targeted therapies.
ISSN:2366-1070
2366-1089
DOI:10.1007/s40487-019-00108-x